Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inmed Pharmaceuticals Inc (NQ: INM ) 0.2667 +0.0017 (+0.64%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Inmed Pharmaceuticals Inc < Previous 1 2 ... 7 8 9 10 11 12 13 14 Next > CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT January 19, 2022 Via Investor Brand Network Topics Supply Chain Exposures Supply Chain CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT January 19, 2022 Via CannabisNewsWire Topics Supply Chain Exposures Supply Chain 4 Penny Stocks Insiders Are Buying January 07, 2022 When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... Via Benzinga InMed Pharmaceuticals' Issues Annual Shareholder Letter January 05, 2022 InMed Pharmaceuticals (NASDAQ: Via Benzinga InMed Pharmaceuticals’ (NASDAQ: INM) Issues Annual Shareholder Letter January 05, 2022 Via Investor Brand Network BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook January 05, 2022 Via Investor Brand Network InMed Pharmaceuticals to Present at Tribe Public's Webinar Event December 30, 2021 InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and... Via Benzinga InMed Pharmaceuticals (NASDAQ: INM) to Present at Tribe Public’s Webinar Event December 30, 2021 Via Investor Brand Network BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Tribe Public’s Webinar Event December 30, 2021 Via Investor Brand Network InMed Pharmaceuticals Announces Publication of Article on CBN as Possible Glaucoma Treatment December 20, 2021 InMed Pharmaceuticals (NASDAQ: Via Benzinga InMed Pharmaceuticals (NASDAQ: INM) Announces Publication of Article on CBN as Possible Glaucoma Treatment December 20, 2021 Via Investor Brand Network BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment December 20, 2021 Via Investor Brand Network InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment December 10, 2021 InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following... Via Benzinga InMed Pharmaceuticals’ (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment December 10, 2021 Via Investor Brand Network BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment December 09, 2021 Via Investor Brand Network InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs December 01, 2021 InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio... Via Benzinga Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs November 30, 2021 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs November 30, 2021 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update November 29, 2021 InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 November 29, 2021 Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: Via Benzinga InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs November 29, 2021 Via Investor Brand Network InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs November 29, 2021 Via CannabisNewsWire InMed Pharmaceuticals Announces Participation in Upcoming Cannabis Conference November 23, 2021 InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis... Via Benzinga Topics Cannabis Exposures Cannabis InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Cannabis Conference November 23, 2021 Via Investor Brand Network Topics Cannabis Exposures Cannabis Welcome to the Party $INM! Competition or Compliment to $SNDL? — Cannabis Daily November 18, 2021 November 18, 2021 The Best Daily Overview Of The Cannabis Space South Dakota lawmakers recommend bill to legalize marijuana. New York ban... Via Benzinga Topics Cannabis Exposures Cannabis 54 Biggest Movers From Yesterday November 19, 2021 Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company... Via Benzinga Exposures Product Safety 44 Stocks Moving In Thursday's Mid-Day Session November 18, 2021 Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the... Via Benzinga Exposures Product Safety Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday November 18, 2021 Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! Via InvestorPlace 24 Stocks Moving in Thursday's Pre-Market Session November 18, 2021 Gainers Sono Group N.V. (NASDAQ: SEV) rose 33% to $50.80 in pre-market trading. Sono Group shares climbed 155% on Wednesday after the company priced its IPO at $15 per share.... Via Benzinga Topics Initial Public Offering Exposures Securities Market InMed Pharmaceuticals Working to Address Rare Cannabinoid Opportunities November 17, 2021 InMed Pharmaceuticals (NASDAQ: Via Benzinga < Previous 1 2 ... 7 8 9 10 11 12 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.